Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age~* Male or female patients (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception).~* Patients undergoing complex\* cardiac surgery on CPB and having systolic PAP \> 40 mmHg or mean PAP \> 30 mmHg (\*surgery on 2 valves, 1 valve and revascularization, or reoperation of a valve)~* Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary hypertension due to left heart disease with systolic PAP \> 60 mmHg~* Signed written informed consent~Exclusion Criteria:~* Systolic blood pressure \< 100 mmHg~* Significant chronic lung disease~* Emergency surgery~* Pregnant/breast-feeding~* Investigational drug use within 28 days prior to randomization~* Complex adult congenital heart disease.~* Severe concomitant illness limiting life expectancy to \< 6 months~* Participation in a device study that will affect the outcome of the study~* Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary arterial hypertension~* Known hypersensitivity to tezosentan or drugs of the same class, or any of their excipients~* Severe liver impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Tezosentan
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).